Coronary
Editorial Comment
Assessing Oral Beta-Blocker Therapy After Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: The Role of Observational Data

https://doi.org/10.1016/j.jcin.2014.04.002Get rights and content
Under an Elsevier user license
open archive

Key Words

beta-blocker therapy
myocardial infarction
percutaneous intervention
ST-segment elevation

Cited by (0)

Dr. Granger has received research funding from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic Foundation, Merck and Company, Pfizer Inc., Sanofi-Aventis, Takeda, The Medicines Company, and Bayer HealthCare; and consulting fees and/or honoraria from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-LaRoche, Lilly, Pfizer Inc., Sanofi-Aventis, Takeda, The Medicines Company, AstraZeneca, Daiichi Sankyo, Ross Medical Corporation, Janssen Pharmaceuticals, and Salix Pharmaceuticals. Dr. Rao has received research funding from Medtronic Foundation.

Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.